China: Life Sciences, Biotechnology & Nanotechnology

The Asia-Pacific Economic Cooperation held a High-Level Policy Dialogue on Agricultural Biotechnology in Dalian, China, where participants explored how genome technologies are transforming food production across the region. Experts demonstrated innovations ranging from fish bred with fewer bones to rice varieties designed for diabetic populations, while addressing the critical challenge of public perception and regulatory frameworks. The dialogue emphasized science-based regulation and consumer education as

Senators Pete Ricketts and Elissa Slotkin have introduced bipartisan legislation that would subject American investments in adversary biotechnology to federal review requirements. The Biotech Investment National Security Act would amend the COINS Act to include pharmaceutical and biological product development in the list of sectors requiring Treasury Department screening for outbound investments to countries of concern, particularly China.

China's regulators intensified anti-corruption enforcement in the life sciences sector during the first half of 2026, introducing stricter oversight of medical data security, sales representatives, and public procurement processes. New administrative measures and judicial interpretations have lowered thresholds for criminal liability while expanding corporate accountability for employee misconduct.

China's National Medical Products Administration has finalized groundbreaking regulatory data protection measures that grant up to 6 years of market exclusivity for innovative drugs, fundamentally...

近日，国家知识产权局遴选出十件关注度高、影响力大、具备指导价值的2025年度专利复审无效典型案例，以深入阐释专利审查标准，明晰专利保护规则...

China's national intellectual property administration (CNIPA) has released ten typical cases from 2025 involving patent reexamination and invalidation. These cases were selected because they are highly relevant...

In recent years, China's regulatory framework for human genetic resources has matured. Regulatory authorities have issued and updated a series of legal documents...

On August 28, 2024, the National Medical Products Administration (NMPA) released the Medical Device Administration Law (Draft for Comment)...

The fourth amendment to the Patent Law of the People's Republic of China (hereinafter, the "Patent Law") came into effect on June 1, 2021. In July of the same year, the Measures for the Implementation...